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Records of female breast cancer patients were selected from a
clinical cancer registry and separated into three cohorts according
to HER2-status (human epidermal growth factor receptor 2) and
treatment with or without Trastuzumab (a humanized monoclonal
antibody). Propensity score matching was used to balance the
cohorts. Afterwards, documented information about disease
events (recurrence of cancer, metastases, remission of local/
regional recurrences, remission of metastases and death) found in
the dataset was leveraged to calculate the annual transition
probabilities for every cohort.
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Value of the data
 Numbers of events (recurrences, metastases and death) are based on a patient cohort collected in a
routine care environment, i.e., real world data.
 Comparison of raw numbers could serve as benchmarks for other cancer registries, hospitals, etc.
 Transition probabilities are estimated based on real world data only and could be used in other
health economic Markov models.
 Transition probabilities could be utilized for validation procedures of other health economic
models.1. Data
We observed the disease progress for HER2-positive and HER2-negative patients in a routine care
setting, i.e., real world setting.
Data is presented twofold:
) Number of patients which shift from a deﬁned health state (Disease free, Recurrence, Metastasis,
Remission recurrence, Remission metastasis, Death) to another.
) Transition probabilities for every year over a time horizon of H¼8 years.
Numbers and transition probabilities are reported for every cohort:
C-1: HER2-positive patients/not treated with Trastuzumab
C-2: HER2-positive patients/treated with Trastuzumab
C-3: HER2-negative patients/not treated with Trastuzumab.2. Experimental design, materials and methods
2.1. Patients
Our patient cohort comprised n¼3230 cases of female breast cancer diagnosed from 01-01-2004
till 31-12-2012 and documented at the clinical cancer registry of the Cancer Center Heilbronn-
Franken (CC). Patients were included in the cohort according to the HERA (Herceptin Adjuvant Trial)-
study protocol's inclusion/exclusion criteria [1] as far as the criteria were applicable to the local
documentation setting. This yielded 892 matching cases.
M. Pobiruchin et al. / Data in Brief 7 (2016) 654–657656Afterwards patients were separated according to HER2-status and treatment with Trastuzumab.
This cohort was separated into four subcohorts C-1 (positive HER2-status and no Trastuzumab
treatment), C-2 (positive HER2-status and Trastuzumab treatment), C-3 (negative HER2-status and no
Trastuzumab treatment) and C-4 (negative HER2-status and Trastuzumab treatment). However,
cohort C-4 needed to be excluded from further analyses, since from a clinical point of view it is not
appropriate to treat HER2-negative patients with Trastuzumab. We assume that there are either
misclassiﬁcations or documentation errors in these three records.
2.2. Propensity score matching
A ﬁrst patient characteristics analysis of the cohorts C-1 to C-3 revealed that there were differ-
ences with respect to the distribution of age, tumor sizes, hormone receptor status, etc. Therefore, we
balanced cohorts C-1 to C-3 with the propensity score matching method [2]. For this step, we used
the MatchIt-package for the statistical software R which implements the nearest neighbor method
[3]. Cohort C-2 served as reference population for the matching process. After this step, every cohort
comprised 138 cases.
2.3. Database extraction
Several health states (Disease free, Recurrence, Metastasis, Remission recurrence, Remission metas-
tasis, Death) were deﬁned beforehand according to a reference study by Blank et al. [4]. These deﬁ-
nitions were used to automatically generate SQL (Structured Query Language) scripts which extracted
the patients' events. Thus raw numbers for the occurrence of several events (or states), e.g., getting a
metastasis or death, could be determined. For a detailed description on how disease state information
were mapped against the local tumor documentation system, the generation of SQL scripts and the
processing of the results please refer to the research article for this data article [5].
2.4. Estimation of transition probabilities
Based on the extracted health state information and the patients' transitions between these states,
maximum likelihood estimation of the transition matrix for the probability of any shift was per-
formed [6] and compared to probabilities used in the model generated by [4]. Thus, the transition
probabilities presented in the Supplementary material (Table 1) of this article were calculated.Acknowledgments
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